A trial looking at camizestrant for early breast cancer (CAMBRIA-2)

This trial is looking at a new drug called camizestrant for early breast cancer that has a medium to high risk of coming back. It is comparing camizestrant with standard hormone treatment.

It is for people whose breast cancer has:

• many receptors for the hormone oestrogen (ER positive cancer) and

• only a small number or no receptors for HER2. This is HER2 negative breast cancer.

You pronounce camizestrant as cami-zess-trant.